EGFR and breast cancer: Pyrotinib, a pan-ErbB inhibitor which was designed to target HER2 in breast cancer and NSCLC, showed potent binding activity to G719A (Figure 4F), which was observed conferring similar molecular interactions like afatinib, dacomitinib and osimertinib.